Biomarin Pharmaceuticals
(BMRN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -23,848 | -77,211 | -117,042 | -630,210 | -171,799 |
| Depreciation Amortization | 103,300 | 96,029 | 90,938 | 98,212 | 49,364 |
| Income taxes - deferred | -82,760 | -68,378 | 44,464 | -228,054 | -76,827 |
| Accounts receivable | -37,852 | -54,274 | -25,256 | -51,483 | -16,367 |
| Other Working Capital | -101,092 | -49,420 | -93,963 | -160,276 | 46,332 |
| Other Operating Activity | 190,514 | 173,462 | 92,102 | 743,974 | -50,202 |
| Operating Cash Flow | $48,262 | $20,208 | $-8,757 | $-227,837 | $-219,499 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 108,188 | 358,981 | -229,487 | -332,180 | -448,471 |
| PPE Investments | -145,026 | -144,620 | -199,219 | -148,380 | -227,653 |
| Net Acquisitions | N/A | N/A | N/A | -2,789 | -538,392 |
| Purchase Sale Intangibles | 6,620 | 50,000 | 125,000 | N/A | 38,244 |
| Other Investing Activity | 5,812 | 49,990 | 123,247 | -698 | 34,918 |
| Investing Cash Flow | $-31,026 | $264,351 | $-305,459 | $-484,047 | $-1,179,598 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | 481,713 | N/A | N/A |
| Debt Repayment | -5,087 | -374,953 | -26 | N/A | N/A |
| Common Stock Issued | 31,611 | 67,488 | 60,859 | 787,165 | 951,302 |
| Other Financing Activity | -101,198 | -80,542 | -35,401 | -60,057 | -25,579 |
| Financing Cash Flow | $-74,674 | $-388,007 | $507,145 | $727,108 | $925,723 |
| Exchange Rate Effect | 902 | -598 | -3,231 | -3,934 | -5,072 |
| Beginning Cash Position | 493,982 | 598,028 | 408,330 | 397,040 | 875,486 |
| End Cash Position | 437,446 | 493,982 | 598,028 | 408,330 | 397,040 |
| Net Cash Flow | $-56,536 | $-104,046 | $189,698 | $11,290 | $-478,446 |
| Free Cash Flow | |||||
| Operating Cash Flow | 48,262 | 20,208 | -8,757 | -227,837 | -219,499 |
| Capital Expenditure | -145,026 | -144,620 | -199,219 | -148,380 | -227,653 |
| Free Cash Flow | -96,764 | -124,412 | -207,976 | -376,217 | -447,152 |